Danaher Co. (NYSE:DHR) Shares Bought by Larson Financial Group LLC

Larson Financial Group LLC grew its holdings in Danaher Co. (NYSE:DHR) by 761.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,481 shares of the conglomerate’s stock after buying an additional 2,193 shares during the quarter. Larson Financial Group LLC’s holdings in Danaher were worth $574,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of DHR. BKM Wealth Management LLC purchased a new stake in shares of Danaher during the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher during the fourth quarter worth about $29,000. OFI Invest Asset Management acquired a new position in Danaher during the third quarter worth about $30,000. Rakuten Securities Inc. acquired a new stake in shares of Danaher during the 4th quarter valued at approximately $36,000. Finally, GHP Investment Advisors Inc. raised its holdings in Danaher by 540.0% during the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after purchasing an additional 135 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE:DHR opened at $253.11 on Wednesday. The business’s 50-day simple moving average is $248.95 and its 200 day simple moving average is $230.64. The company has a market cap of $187.44 billion, a P/E ratio of 39.61, a PEG ratio of 3.96 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. Danaher Co. has a one year low of $182.09 and a one year high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.87 earnings per share. On average, sell-side analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is currently 16.90%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DHR shares. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Robert W. Baird lifted their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. KeyCorp increased their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Citigroup increased their target price on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $268.00.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,957 shares of company stock valued at $8,265,802. 10.90% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.